Print

CureDuchenne Media Statement Regarding ProSensa Holding N.V. (RNA) Announcement Of Regulatory Path Forward For Drisapersen As A Potential Treatment For DMD  
6/3/2014 10:01:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, issued the following statement today regarding the announcement by Prosensa Holding N.V. (NASDAQ: RNA) that the United States Food and Drug Administration (FDA) has outlined a regulatory path forward, under an accelerated approval pathway, for drisapersen, a potential treatment for Duchenne Muscular Dystrophy (DMD):

Help employers find you! Check out all the jobs and post your resume.

//-->